| Revision as of 09:39, 20 July 2006 editBluebot (talk | contribs)349,597 edits formatting← Previous edit | Latest revision as of 20:26, 20 August 2022 edit undoCitation bot (talk | contribs)Bots5,415,305 edits Alter: title. | Use this bot. Report bugs. | Suggested by BrownHairedGirl | #UCB_webform 2887/3836 | ||
| (51 intermediate revisions by 31 users not shown) | |||
| Line 1: | Line 1: | ||
| Dr. '''Thomas McGlashan''' is |
Dr. '''Thomas McGlashan''' (born 1942) is an American professor of ] at ], well known for his academic contributions to the study of schizophrenia and other mental illnesses. | ||
| == Professional career == | |||
| Disapppointed with psychoanalysis, Dr. McGlashan then studied the benefits of antipsychotic medical drugs. In the 1990's he embarked on a study of how useful such drugs can be in preventing ] in adolescents at high risk. In May ], "Dr. McGlashan reported that the drugs were more likely to induce weight gain than to produce a significant, measurable benefit." | |||
| He obtained his medical qualification from the University of Pennsylvania in 1967, and was a staff member in ], where according to the ], May 23, 2006, McGlashan "strived for years to master ], only to reject it (for psychosis) after demonstrating, in a landmark 1984 study, that the treatment did not help much at all in people ... with ].".<ref>{{cite news |first=Benedict |last=Carey |title=A Career That Has Mirrored Psychiatry's Twisting Path |url=https://www.nytimes.com/2006/05/23/health/psychology/23prof.html |work=The New York Times |date=2006-05-23 |access-date=2008-01-18}}</ref> These long term follow up and reported outcomes for patients with schizophrenia are known as the Chestnut Lodge studies.<ref>{{cite journal |author=McGlashan TH |title=The Chestnut Lodge follow-up study. I. Follow-up methodology and study sample |journal=Arch. Gen. Psychiatry |volume=41 |issue=6 |pages=573–85 |date=June 1984 |pmid=6428370 |doi= 10.1001/archpsyc.1984.01790170047006}}</ref> | |||
| In the 1990s he embarked upon work focused on interventions early in the course of schizophrenia, and became an early advocate and researcher in early detection and ],<ref>{{cite journal |author=McGlashan TH |title=Early detection and intervention in schizophrenia: editor's introduction |journal=Schizophr Bull |volume=22 |issue=2 |pages=197–9 |year=1996 |pmid=8782281 |doi= 10.1093/schbul/22.2.197|url=http://schizophreniabulletin.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=8782281|doi-access=free }}</ref> including being a key participant in the Norway early detection studies (TIPS) <ref>{{cite journal |author=Johannessen JO |title=Pathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study |journal=Br J Psychiatry Suppl |volume=48 |issue= 48|pages=s24–8 |date=August 2005 |pmid=16055803 |doi=10.1192/bjp.187.48.s24 |name-list-style=vanc|author2=Larsen TK |author3=Joa I |display-authors=3 |last4=Melle |first4=I |last5=Friis |first5=S |last6=Opjordsmoen |first6=S |last7=Rund |first7=BR |last8=Simonsen |first8=E |last9=Vaglum |first9=P|doi-access=free }}</ref> and PRIME studies on early treatment of those at risk of schizophrenia <ref>{{cite journal |author=McGlashan TH |title=The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design |journal=Schizophr. Res. |volume=61 |issue=1 |pages=7–18 |date=May 2003 |pmid=12648731 |doi= 10.1016/S0920-9964(02)00439-5|name-list-style=vanc|author2=Zipursky RB |author3=Perkins D |author3-link=Diana Perkins|display-authors=3 |last4=Addington |first4=J |last5=Miller |first5=T.J |last6=Woods |first6=S.W |last7=Hawkins |first7=K.A |last8=Hoffman |first8=R |last9=Lindborg |first9=S|s2cid=1118339 }}</ref> The study reported that the drug ] had a "trend ]" effect in preventing conversion to psychosis and that further, larger studies are warranted.<ref>{{cite journal |author=McGlashan TH |title=Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis |journal=Am J Psychiatry |volume=163 |issue=5 |pages=790–9 |date=May 2006 |pmid=16648318 |doi=10.1176/appi.ajp.163.5.790 |url=https://cdr.lib.unc.edu/record/uuid:78a1ed77-325d-4d2a-b6e2-66305d76868d|name-list-style=vanc|author2=Zipursky RB |author3=Perkins D |display-authors=3 |last4=Addington |first4=J. |last5=Miller |first5=T. |last6=Woods |first6=S. W. |last7=a. Hawkins |first7=K. |last8=e. Hoffman |first8=R. |last9=Preda |first9=A.}}<!-- https://cdr.lib.unc.edu/concern/articles/s1784n86w--></ref> | |||
| Professor Thomas McGlashan is the current recipient of the Richard Wyatt Award,<ref>{{cite web |url=http://iepa.org.au/ContentPage.aspx?pageID=53 |title=The Richard J. Wyatt Award |access-date=2010-06-23 |url-status=dead |archive-url=https://web.archive.org/web/20091030084951/http://iepa.org.au/%28S%283pj0pb45hafcpw45vzeryh45%29%29/ContentPage.aspx?pageID=53 |archive-date=2009-10-30 }}</ref> of the ], and of the Psychiatric Research Award of the ] for his contributions to the field of early detection and intervention in psychosis. | |||
| {{psych-stub}} | |||
| == Books == | |||
| * ''The documentation of clinical psychotropic drug trials'' by Thomas H McGlashan - 1973) | |||
| * ''The Borderline: Current Empirical Research'' by Thomas H. McGlashan (1985) | |||
| '''Co-authored:''' | |||
| * ''Early Intervention in Psychotic Disorders'' (Nato Science Series: D Behavioural and Social Sciences, Volume 91) (NATO Science Series D: (closed)) by Tandy Miller, Sarnoff A. Mednick, Thomas H. McGlashan, and Jan Libiger (Hardcover - Nov 2001) | |||
| * ''Schizophrenia: Treatment Process and Outcome'' by Thomas H. McGlashan and Christopher J. Keats (1989) | |||
| * ''A Developmental Model of Borderline Personality Disorder: Understanding Variations in Course and Outcome'' by Patricia Hoffman Judd and Thomas H. McGlashan (2002) | |||
| == References == | |||
| {{reflist|2}} | |||
| <!-- Goes above DEFAULTSORT/Categories --> | |||
| {{Authority control}} | |||
| {{DEFAULTSORT:McGlashan, Thomas}} | |||
| ] | |||
| ] | |||
| ] | |||
| ] | |||
| ] | |||
| {{US-psychiatrist-stub}} | |||
Latest revision as of 20:26, 20 August 2022
Dr. Thomas McGlashan (born 1942) is an American professor of psychiatry at Yale University, well known for his academic contributions to the study of schizophrenia and other mental illnesses.
Professional career
He obtained his medical qualification from the University of Pennsylvania in 1967, and was a staff member in Chestnut Lodge, where according to the New York Times, May 23, 2006, McGlashan "strived for years to master psychoanalysis, only to reject it (for psychosis) after demonstrating, in a landmark 1984 study, that the treatment did not help much at all in people ... with schizophrenia.". These long term follow up and reported outcomes for patients with schizophrenia are known as the Chestnut Lodge studies.
In the 1990s he embarked upon work focused on interventions early in the course of schizophrenia, and became an early advocate and researcher in early detection and intervention for psychosis, including being a key participant in the Norway early detection studies (TIPS) and PRIME studies on early treatment of those at risk of schizophrenia The study reported that the drug Olanzapine had a "trend significant" effect in preventing conversion to psychosis and that further, larger studies are warranted.
Professor Thomas McGlashan is the current recipient of the Richard Wyatt Award, of the International Early Psychosis Association, and of the Psychiatric Research Award of the American Psychiatric Association for his contributions to the field of early detection and intervention in psychosis.
Books
- The documentation of clinical psychotropic drug trials by Thomas H McGlashan - 1973)
- The Borderline: Current Empirical Research by Thomas H. McGlashan (1985)
Co-authored:
- Early Intervention in Psychotic Disorders (Nato Science Series: D Behavioural and Social Sciences, Volume 91) (NATO Science Series D: (closed)) by Tandy Miller, Sarnoff A. Mednick, Thomas H. McGlashan, and Jan Libiger (Hardcover - Nov 2001)
- Schizophrenia: Treatment Process and Outcome by Thomas H. McGlashan and Christopher J. Keats (1989)
- A Developmental Model of Borderline Personality Disorder: Understanding Variations in Course and Outcome by Patricia Hoffman Judd and Thomas H. McGlashan (2002)
References
- Carey, Benedict (2006-05-23). "A Career That Has Mirrored Psychiatry's Twisting Path". The New York Times. Retrieved 2008-01-18.
- McGlashan TH (June 1984). "The Chestnut Lodge follow-up study. I. Follow-up methodology and study sample". Arch. Gen. Psychiatry. 41 (6): 573–85. doi:10.1001/archpsyc.1984.01790170047006. PMID 6428370.
- McGlashan TH (1996). "Early detection and intervention in schizophrenia: editor's introduction". Schizophr Bull. 22 (2): 197–9. doi:10.1093/schbul/22.2.197. PMID 8782281.
- Johannessen JO, Larsen TK, Joa I, et al. (August 2005). "Pathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study". Br J Psychiatry Suppl. 48 (48): s24–8. doi:10.1192/bjp.187.48.s24. PMID 16055803.
- McGlashan TH, Zipursky RB, Perkins D, et al. (May 2003). "The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design". Schizophr. Res. 61 (1): 7–18. doi:10.1016/S0920-9964(02)00439-5. PMID 12648731. S2CID 1118339.
- McGlashan TH, Zipursky RB, Perkins D, et al. (May 2006). "Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis". Am J Psychiatry. 163 (5): 790–9. doi:10.1176/appi.ajp.163.5.790. PMID 16648318.
- "The Richard J. Wyatt Award". Archived from the original on 2009-10-30. Retrieved 2010-06-23.
This article about a United States psychiatrist is a stub. You can help Misplaced Pages by expanding it. |